Upfront Briefing
Risk ripped back on — Trump waved off the Iran strikes, oil exhaled, and biotech actually tagged along for once. Novo handed the UK its first weight-loss pill, Takeda took a bat to BMS's Sotyktu in a head-to-head, and Penumbra sweet-talked the FDA into a stroke clearance. Underneath the marquee names, Stockholm kept the EHA data spigot running and the IPO window stayed wide open — Kardigan lining up a $320M debut while Enliven passed the hat the old-fashioned way: more stock, more warrants, more dilution. Cash still talks; it just costs more.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,394.3 |
+1.8% |
+7.8% |
| Nasdaq 100 |
29,446.2 |
+3.3% |
+16.8% |
| Russell 2000 |
2,921.0 |
+3.0% |
+16.5% |
| Healthcare (XLV) |
154.1 |
+0.8% |
(0.9%) |
| Biotech (XBI) |
132.7 |
+3.0% |
+9.2% |
| Nasdaq Biotech (NBI) |
5,923.5 |
+2.8% |
+3.8% |
| Clinical Trials (BBC) |
42.2 |
+3.8% |
+12.2% |
|
- Biotech brought its own catalysts to the risk-on tape: Novo's oral Wegovy cleared the UK, Takeda's zasocitinib beat Sotyktu head-to-head, and Penumbra won FDA stroke clearance — XBI +3.0%, NBI +2.8%, BBC +3.8%.
- The broad tape ripped on Middle East de-escalation: Trump called off planned strikes on Iran and flagged a deal "close," sending the S&P +1.8% and Nasdaq 100 +3.3%, WTI crude (2.6%) to $87.71, and the VIX down ~12%.
- Market data: U.S. cash close Thursday, 11 June 2026.
The Big 3
|
1
|
Novo's oral Wegovy wins UK approval
|
- The MHRA cleared semaglutide tablets as the UK's first daily GLP-1 weight-loss pill, on OASIS 4 data; available privately within weeks and not yet NHS-assessed.
- Why it matters: The MHRA nod makes oral Wegovy the first daily GLP-1 weight-loss pill in the UK — not a global first, though, since the FDA cleared the same 25mg tablet in December and Novo launched it stateside in January. OASIS 4 anchors the label: ~14% mean weight loss vs ~2% on placebo at 64 weeks (n=307), ~17% in patients who stayed on drug. Convenience is the moat here — a pill pressures Lilly's orforglipron on the one axis injectables can't defend and pulls in patients who'd never touch a needle. The catch is reimbursement: no NICE assessment yet, so UK scripts are private-pay only for now, and supply scale-up still gates how fast it ramps.
- Source: BioSpace
- More: Novo Nordisk
|
|
2
|
Takeda's zasocitinib tops BMS's Sotyktu head-to-head
|
- In a Phase 3 head-to-head, Takeda's TYK2 inhibitor zasocitinib hit PASI 100 (complete skin clearance) in more than 35% of plaque-psoriasis patients at Week 16 — described as ~2.5x Sotyktu — and beat it on all key secondaries.
- Why it matters: The head-to-head erases the cross-trial asterisk and pays off Takeda's $4B Nimbus bet just as it lines up a 1H 2027 launch. It's an ugly read for BMS — Sotyktu managed only $291M last year against what was once a $4B ambition, and it's now lost head-to-heads to both zasocitinib and J&J/Protagonist's Icotyde, which cleared the FDA in March. With Alumis's TYK2 filing in Q4, the oral I&I shelf is filling fast. Worth holding the champagne, though — Takeda gave topline only, so the size of the beat still rides on the full dataset.
- Source: Fierce Biotech
- More: Takeda
|
| 3 | Penumbra THUNDERBOLT cleared by FDA for stroke |
-
Penumbra's THUNDERBOLT received FDA clearance for acute ischemic stroke. The device is described as the first CAVT platform to deliver modulated aspiration for stroke.
- Why it matters: Clearance hands Penumbra (PEN, ~$12.5B) the only computer-assisted vacuum thrombectomy device on the US market and stretches its modulated-aspiration franchise from peripheral clots into the brain. Share in stroke gets won on first-pass clot removal, not label language — so the real test is how THUNDERBOLT's recanalization stacks up against the stent retrievers and aspiration rigs from Stryker, Medtronic and J&J. The clearance de-risks the launch clock; the THUNDER registry reads are what actually move the competitive needle.
-
Source:
MassDevice
-
More:
PR
|
Everything Else that broke
- Fresh EHA data landed: Caribou's allogeneic anti-CD19 CAR-T vispa-cel posted 17.1-month median PFS in second-line LBCL (n=27), numerically topping Breyanzi (14.8mo) and Yescarta (14.9mo) — Fierce Biotech; and Kyntra's roxadustat showed durable transfusion independence in lower-risk MDS regardless of ring-sideroblast status (MATTERHORN post-hoc), lifting KYNB ~4% after hours — PR
- Akeso's gumokimab won China's NMPA approval for moderate-to-severe plaque psoriasis in adults. — PR
- Sensorion dropped its OTOF hearing-loss gene therapy and shifted focus to GJB2. — BioPharma Dive
- Genentech cut staff in a gRED restructuring, shuttering its infectious disease and physiological chemistry units and exiting three VPs. — Endpoints
- Novo Nordisk disclosed an IT security incident but said core operations remain running. — PR
- Rising healthcare costs next year could tighten utilization and pricing scrutiny. — Endpoints
- Drugmakers are leaning on logistics providers as trade disruptions linger. — Endpoints
- Ascendis posted 5-year Phase 2 TransCon PTH durability data in hypoparathyroidism. — PR
- BioCentury says the political calendar may delay FDA reform into November. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
GHO Capital and CBC Group are combining investment platforms across healthcare. — BioCentury
VC / Private Financings
- Ethyreal launched with $101M to enter the Tepezza-linked thyroid eye disease arena. — BioCentury
IPOs / Follow-Ons
- Kardigan set terms for a ~$320M Nasdaq IPO (23.3M shares at $14–16), with lead cardiac myosin activator danicamtiv in Phase 2b/3 for genetic dilated cardiomyopathy. — Fierce Biotech
- Enliven priced an upsized public offering of common stock and pre-funded warrants. — PR
- Summit withdrew its planned $500M share sale a day after launch. — Endpoints
Academic Corner - Spatial CRISPR screens mapped total RNA in tissue, adding a sharper tool for native microenvironment biology. — Nature Biotech
- Nature Medicine profiled microglia around plaques and tau to separate silent Alzheimer's disease from decline. — Nature Medicine
- Nature RDD highlighted the FDA approval of an antiviral peptide for hepatitis delta virus infection. — Nature RDD
|
